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C12, an attenuated, fusion delayed, very weakly hepatotropic mutant of mouse hepatitis virus strain A59 (MHV-A59)
has been further characterized. We have previously shown that C12 has two amino acid substitutions relative to wild
type virus in the spike protein, Q159L (within a region of S1 shown to bind to viral receptor in an in vitro assay) and
H716D (in the proteolytic cleavage recognition site). We have sequenced the rest of the 31-kb genome of C12 and
compared it to wild type virus. Only three additional amino acids substitutions were found, all encoded within the
replicase gene. Analysis of C12 in vivo in C57Bl/6 mice has shown that despite the fact that this virus replicates in
the brain to titers at least as high as wild type and causes acute encephalitis similar to wild type, this virus causes a
minimal level of demyelination and only at very high levels of virus inoculation. Thus acute encephalitis is not sufficient
for the induction of demyelination by MHV-A59. Analysis of mutants isolated at earlier times from the same persistently
infected glial cell culture as C12, as well as mutants isolated from a second independent culture of persistently infected
glial cells, suggests that both the weakly demyelinating and the weakly hepatotropic phenotypes of C12 are associated
with the Q159L amino acid substitution. q 1997 Academic Press

INTRODUCTION

for the altered pathogenic properties of the mutant viruses, we compared the sequence of the spike (S) genes
of wild type and mutant viruses isolated from persistently
infected glial cells cultures. We focused on the S protein
because this protein mediates both binding to the viral
receptor (Holmes and Compton, 1995) and cell to cell
fusion. This, in combination with the fact that viruses
with mutations in the S gene have altered pathogenic
properties (Fleming et al., 1986; Gallagher et al., 1990)
suggest that S is a major determinant of viral tropism.
The fusion-delayed phenotype was shown to result from
the substitution of an aspartic acid residue for a histidine
(H716D) in the basic sequence that serves as a recognition signal for proteolytic cleavage of the S protein (Gombold et al., 1993). This amino acid substitution prevents
cleavage of the 180-kDa precursor S protein into the two
approximately 90-kDa subunits, S1 and S2 (Luytjes et al.,
1987; Gombold et al., 1993). Aside from the cleavage
recognition site mutation (H716D), all the mutant viruses
examined contained one, and only one, additional amino
acid substitution in S, Q159L, located within the amino
terminal portion of the S1 subunit. Analysis of fusion
competent revertant viruses, however, showed that attenuation and loss of hepatotropism were not linked to the
fusion phenotype and did not map to the H716D amino
acid substitution. An association between the Q159L mutation and loss of hepatotropism was demonstrated by
the analysis of other mutants isolated from persistently
infected cultures (Hingley et al., 1994). This supports the

The murine coronavirus, mouse hepatitis virus strain
A59 (MHV-A59), produces both hepatitis and neurological disease in susceptible mice. Neurological disease
includes both acute meningoencephalitis and chronic
demyelinating disease (Lavi et al., 1984b). In vitro, MHVA59 causes a lytic infection in mouse fibroblast cells,
but a persistent productive, nonlytic infection of primary
cultured glial cells (Lavi et al., 1987). The mechanism of
demyelination is not well understood but it is thought to
involve elements of direct viral infection as well as an
immune mediated component (Houtman and Fleming,
1996a).
We have been using a group of MHV-A59 mutants with
altered pathogenic properties to map the determinants of
central nervous system pathogenesis and to understand
what features of infection of mice lead to demyelination.
We have previously characterized this group of attenuated, fusion-delayed mutants, which were isolated from
persistently infected glial cells. These mutants had
greatly reduced ability to replicate in the liver and cause
hepatitis (Hingley et al., 1994).
In order to begin to identify the mutations responsible
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hypothesis that this mutation may play a role in tissue
tropism. Interestingly, Q159L lies within the amino terminal 330 amino acids of S1, a region of the spike protein
demonstrated to bind to the viral receptor in an in vitro
assay (Kubo et al., 1994; Suzuki and Taguchi 1996), suggesting the possibility that this amino acid may influence
the interaction of the spike protein with the viral receptor.
Earlier studies (see Table 1) also demonstrated that
viruses with identical S gene sequences had different
virulence and hepatotropism phenotypes (Hingley et al.,
1994). Thus, to determine which additional genes may
influence pathogenesis, we have sequenced the entire
genome of the C12 mutant of MHV-A59, one of the viruses isolated from persistently infected glial cells (Gombold et al., 1993; Hingley et al., 1994). In addition to the
two mutations found in the S gene, there were only five
other mutations; of these, three resulted in amino acid
substitutions, all within the viral replicase gene.
We describe here the further characterization of the
C12 mutant. We have shown that despite the fact that C12
replicates in the brain and causes encephalitis similar to
that of wild type virus, at a dose of 5000 PFUs (2 wild
type LD50), at which wild type virus induces extensive
demyelination in all infected animals, C12 does not induce detectable demyelination. Analysis of other mutants
isolated at earlier time points from persistently infected
glial cell cultures (Hingley et al., 1994) as well as mutants
isolated from an independent culture of persistently infected glial cells, suggests that the Q159L mutation, and
not the three replicase mutations, is associated with loss
of the ability to demyelinate efficiently as well as the loss
of the ability to induce hepatotropism.

fin and sectioned for staining with luxol fast blue to detect
plaques indicative of demyelination. For each of five mice
at each dose of virus, demyelination was quantitated by
examining one spinal cord section (four quadrants) from
each of five levels of spinal cord; thus there were 100
quadrants examined for each dose of virus. The experiments were designed so that there would be five animals
surviving acute infection even at high doses of virus relative to the LD50 ; however, in the case of the highest dose
of C3 and all doses of B12, there were less than five
surviving animals (Figs. 2 and 3). Demyelination was also
verified in the brain by staining with luxol fast blue.

METHODS

RESULTS

Virus
MHV-A59 was obtained originally from Dr. Lawrence
Sturman (Albany, NY). The mutants were plaque purified
from the supernatant of either the ‘‘C’’ culture of persistently infected glial cells at 1 week (C3), 6 weeks (C5),
12 weeks (C8), and 16 weeks (C12) postinfection or from
the independent ‘‘B’’ culture of persistently infected glial
cells at 18 weeks postinfection (B11, B12) and characterized as previously described (Gombold et al., 1993; Hingley et al., 1994, 1995).

Genome sequencing
For sequencing of the viral genome, reverse transcriptase/polymerase chain reaction amplification (RT/
PCR) was carried out, using as templates, cytoplasmic
RNA extracted from L2 cell monolayers infected with wild
type MHV-A59, C12, C3, C5, C8, B11, or B12. Complementary DNA was synthesized using random oligomers as
primers. MHV-A59-specific primers were designed to
amplify fragments of about 600 base pairs. Doublestranded PCR products were gel purified and analyzed
by automated sequencing using the Taq dye terminator
procedure according to the manufacturer’s protocol (Taq
DyeDeoxy Terminator Cycle Sequencing kit, Applied Biosystems) and the same primers used for amplification.
Each fragment was sequenced in both directions. The
entire C12 genome was sequenced; fragments of each
of the other viruses were sequenced as described under
Results.

Sequence comparison of the genomes of the C12
mutant and MHV-A59

Four- to 6-week-old MHV-free C57Bl/6 mice (Jackson
Laboratories, Bar Harbor, ME) were inoculated intracerebrally with 10-fold serial dilutions of wild type or mutant
MHV-A59. At 30 days postinfection, mice surviving acute
infection were perfused with phosphate-buffered saline,
followed by 10% buffered formalin. Brains and spinal
cords were removed and tissue was embedded in paraf-

We have shown previously that the spike (S) protein
encoded by the C12 mutant has two amino acid substitutions as compared with the wild type S protein. Earlier
studies demonstrated that viruses with the identical S
protein sequence had different virulence and hepatotropism phenotypes (see Table 1). For example the mutant
B11 appeared to be blocked in its spread from the central
nervous system to the liver, while the mutant C12 was
inhibited in its ability to replicate in hepatocytes even
when inoculated directly into the liver (Hingley et al.,
1994). The B12 mutant, while nonhepatotropic like C12,
retained its virulence (Hingley et al., 1994). Thus, we
concluded that these pathogenic properties must also
involve genes outside of S. This, in combination with the
idea that it is difficult to assign phenotypes to specific
sequences in S without knowing if there are any other
mutations outside of S, led us to sequence the rest of
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the C12 genome to identify other possible mutations that
may play a role in these different pathogenicities.
We have sequenced the entire 31-kb genome of C12.
Sequencing was carried out by RT/PCR of viral RNA,
present in infected cells, as described under Materials
and Methods. This generates a consensus sequence
because it is derived from the RNA genome and not
cloned cDNAs; we compared the C12 sequence with the
published sequence for wild type A59 (from our lab as
well as from other labs) (Budzilowicz et al., 1985; Budzilowicz and Weiss, 1987; Zoltick et al., 1990; Bonilla et al.,
1994; Weiss et al., 1993; Bredenbeek et al., 1990; Luytjes
et al., 1987, 1988; Armstrong et al., 1983, 1984). Whenever
we found a difference between C12 and the published
MHV-A59 wild type sequence, we made a new preparation of cDNA from intracellular C12 RNA, amplified the
same double stranded DNA fragment, and verified the
C12 sequence. We then determined if our wild type sequence was the same as the published one. The C12
genome had surprisingly few mutations compared to the
wild type genome after 16 weeks of culture in glial cells.
Figure 1 shows the comparison of the wild type and C12
genomes.
With the exception of the two previously discussed
amino acid substitutions in S, H716D and Q159L (Fig. 1),
there are no amino acid substitutions in the deduced
sequences of any of the structural proteins; this includes
spike (S) (Luytjes et al., 1987; Hingley et al., 1994), matrix
(M) (Armstrong et al., 1984), nucleocapsid (N) (Armstrong
et al., 1983), and small membrane (E) (Budzilowicz and
Weiss, 1987) proteins as well as the open reading frames
(ORFs) for the I protein, encoded within, but out of frame

with, the N protein (Fischer et al., 1997) and the hemagglutinin esterase (HE) protein, which is encoded, but not
expressed in MHV-A59 (Luytjes et al., 1988). The sequence of HE of C12 is identical to the published sequence for wild type MHV-A59 (Luytjes et al., 1988) except for a one-nucleotide deletion which causes a frame
shift near the end of the ORF, resulting in the addition of
eight amino acids to the end of the ORF. This frame shift
mutation is also present in our wild type A59. Thus, our
wild MHV-A59 has an additional mutation in the HE ORF;
this is consistent with the notion that this protein is not
essential in the MHV-A59 life cycle in vitro or in vivo
(Luytjes et al., 1988).
The deduced sequences of the nonstructural proteins
encoded in ORFs 2a, 4, and 5a are also identical for C12
and wild type virus. However, in the 21-kb sequence of
ORF1a and ORF1b of the replicase gene of the C12 genome (Fig. 1), there are three amino acid substitutions
compared to wild type virus. There are two substitutions
in ORF1a (P1699S and M2196K) and one in ORF1b,
R1330S. (The numbers are amino acid numbers starting
from the first amino acid in each ORF.) Of the two substitutions in ORF 1a, P1699S is in the predicted papain-like
proteinase-2 (PLP-2) domain; the substitution in ORF 1b,
R1330S, is in the predicted helicase domain (Lee et al.,
1991; Bredenbeek et al., 1990; Bonilla et al., 1994). There
is only one silent mutation in the genome of C12; nucleotide 2471 of ORF 1a is U rather than C, which is in the
wild type genome.
We have also compared the noncoding regions of C12
and wild type MHV-A59. We have found no differences
between C12 and wild type in the 5* or 3* noncoding
regions. With the exception of the conserved intergenic
region preceding the M gene, there were also no differences between C12 and wild type MHV-A59 intergenic
sequences. There is one nucleotide change in the intergenic region preceding the M gene. In C12 the sequence is AAUCUAAAC instead of AAUCCAAAC present
in wild type MHV-A59 (Budzilowicz et al., 1985).
We examined the early mutants from the C culture for
the presence of the three replicase mutations as well as
the intergenic nucleotide difference. These include the
C3, C5, and C8 mutants isolated at various times after
infection (1, 6, and 12 weeks, respectively). Neither the
replicase mutations (Table 2) nor the intergenic region
mutation were present in any of the early mutants. This
suggested that these mutations arose in the culture later
than either of the S mutations.
In order to determine if these replicase substitutions
were a general characteristic of the attenuated, tropism
mutants that arise in persistently infected glial cells, we
examined the genomes of two mutants, B11 and B12,
isolated from the independent (‘‘B’’) culture of persistently
infected glial cells (Gombold et al., 1993). None of the
three replicase mutations were found in either of these
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TABLE 1
Pathogenic Phenotypes of Mutants Containing Q159L
and H716D Encoded in the S Gene
Hepatitisc
Virus

Virulencea

Encephalitisb

IH

IC

WT-A59
C12
B11
B12

/
0
0
/

/
/
/
/

/
0
/
0

/
0
0
0

a

Virulence is defined by lethal dose (LD)50 or the amount of virus
needed to kill half the weanling C57Bl/6 mice after intracerebral inoculation. A minus sign indicates the LD50 is at least 2 log10 greater than
wild type. These data were taken from Hingley et al. (1994).
b
Encephalitis is a measurement of both replication in the CNS brain
and detection of viral antigen and pathology in brain sections. The data
for WT-A59, C12, and B11 are from Hingley et al. (1994).
c
Hepatitis is defined as replication and detection of viral antigen
and pathology in liver sections after intrahepatic (IH) or intracerebral
(IC) inoculation of mice. A minus sign indicates that virus titer was at
least 2 log10 less than wild type. The data for WT-A59, C12, and B11
are from Hingley et al. (1994).
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FIG. 1. Sequence comparison of the C12 and wild type MHV-A59 genomes. The entire C12 genome was sequenced and the sequence
compared to that of wild type MHV-A59 (as described in the text). (A) Schematic diagram of the viral genome and the location of the five
amino acid substitutions and the one nucleotide change in an intergenic region of C12. The structural proteins are Spike, HE (hemagglutinin
esterase), M (matrix), N (nucleocapsid), E (small membrane), and I (internal ORF). The nonstructural replicase proteins are encoded in ORF
1a and ORF 1b. The domains of the replicase PLP-1 (papain-like proteinase-1) and PLP-2 (papain-like proteinase-2), 3C (poliovirus 3C like
proteinase), Pol (polymerase), and Hel (helicase) were all predicted by Lee et al. (1991). The nonstructural, nonessential protein products of
ORFs 2a, 4, and 5a are not shown. The one silent mutation (nucleotide 2471 is U rather than C, present in the wild type genome) is not shown.
(B) Genes and predicted functional domains which contain these amino acid substitutions. The amino acids are numbered from the beginning
of each open reading frame (ORF) (Bredenbeek et al., 1990; Bonilla et al., 1994; Luytjes et al., 1987). The cleavage site of S was mapped by
Luytjes et al. (1987) and the mapping of the receptor binding domain is from Kubo et al. (1994). The intergenic regions are thought to be
involved in transcriptional regulation (van der Most and Spaan, 1995).

genomes. We then sequenced a larger region around
the mutation in the predicted PLP-2 domain (1100 nucleotides) and the mutation in the predicted helicase domain
(1800 nucleotides) to determine if there were other mutations within either of these predicted domains in B11 or
B12. B11 did have another amino acid substitution within
the PLP-2 domain, V1798M.
We also found several mutations, both silent and coding, in the comparison of wild type MHV-A59 that we
have used to derive the mutants (obtained from Dr. L.
Sturman) as compared to the published sequences
(Bredenbeek et al., 1990; Bonilla et al., 1994; Luytjes et
al., 1987; Luytjes et al., 1988; Hingley et al., 1994; Armstrong et al., 1983, 1984; Budzilowicz et al., 1985; Budzilowicz and Weiss, 1987; Weiss et al., 1993; Zoltick et
al., 1990), some of which came from the sequencing of
another MHV-A59 (obtained from Dr. J. Leibowitz) in our

lab (Bonilla et al., 1994; Budzilowicz et al., 1985; Budzilowicz and Weiss, 1987; Weiss et al., 1993; Zoltick et al.,
1990, unpublished sequences of ORF 1b). Mutations encoding amino acid substitutions included two in ORF 1a,
two in ORF 1b, one in S, one in N, and one each in ORFs
4 and 5a. Additional silent mutations included three in
ORF 1a, two in ORF 1b, and two in N. There were also
two nucleotide changes and two insertions in the 3* noncoding region of the genome.
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Demyelination of C12
We have shown previously that the C12 mutant of
MHV-A59 has a fusion delayed phenotype in vitro (Gombold et al., 1993). Furthermore, C12 replicates to titers
equal to wild type virus in the CNS and causes a similar
level of encephalitis. However, it is very weakly hepato-
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TABLE 2
Pathogenic Properties and Sequences of Mutants Isolated at Various Times from Persistently Infected Glial Cell Cultures
Amino acid substitutions
Spike genea

Replicase geneb

Phenotype

Virus

159

716

1699

2196

1330

Hepatitisc

Demyelinationd

Fusione

WT
C3
C5
C8
C12
B11
B12

Q
Q
L
L
L
L
L

H
H
H
D
D
D
D

P
P
P
P
S
P
P

M
M
M
M
K
M
M

R
R
R
R
S
R
R

/
/
0
0
0
0
0

/
/
0
0
0
0
0

/
/
/
0
0
0
0

a

The amino acids within the spike protein are numbered beginning with the first residue in the open reading frame (ORF) encoding S.
The amino acids in the replicase are numbered from the first residue of ORF 1a (P1699 and M2196) or the first residue of ORF1b (R1330).
c
Hepatitis was measured after intracerebral inoculation as described in Table 1.
d
Demyelination was measured as described under Materials and Methods. A minus sign means that demyelination was minimal as shown in
Figs. 2 and 3.
e
Fusion was defined as previously described Gombold et al., (1993). A negative sign signifies a delayed fusion phenotype in which fusion is
negative when measured in L2 cells at 10 h postinfection but eventually does occur by about 24 h postinfection.
b

tropic (Hingley et al., 1994). In an earlier study (Gombold
et al., 1995), we observed that C12 appeared to demyelinate strikingly less well than wild type virus. To assess
the difference in demyelination more quantitatively, we
measured the amount of demyelination (as described
under Materials and Methods) induced by wild type and
C12 viruses as a function of dose of virus inoculated.
Figure 2 shows these results. For wild type MHV-A59,
the amount of demyelination was approximately linear
with the log10 of the amount of virus inoculated. With a
dose of 5000 PFU (approximately 2 LD50s) of wild type
virus, all the animals infected had demyelination (5/5)
and demyelination was present in approximately 63% of
the spinal cord quadrants examined. We have analyzed
demyelination by wild type MHV-A59 in four experiments.
The range of demyelination was from 59 to 69% of the
quadrants for a dose of 3700 to 5000 PFU; thus the
amount of demyelination is quite reproducible. At the
same dose C12 caused no detectable demyelination.
Even at 100-fold higher dose of inoculation, demyelination was observed in 3/5 of C12 infected animals and
in only 13% of the quadrants (Fig. 2). Thus, despite the
fact that C12 replicates to high titer in the brain and
causes encephalitis to a similar extent as wild type virus
(Hingley et al., 1994), it is a poor inducer of demyelination.
Similar results were obtained with the B11 and B12 mutants, isolated from an independent culture of persistently infected glial cells (Fig. 2).

analysis of the mutants isolated earlier from persistently
infected cultures (Hingley et al., 1994). We have used
the same mutants to ask whether demyelination is also
associated with this mutation or perhaps with the replicase mutations that arise later during persistence. Thus,
the C3, C5, and C8 mutants were analyzed for the ability
to induce demyelination. These results are shown in Fig.
3 and summarized in Table 2. The C3 mutant was able
to induce demyelination with the same efficiency as wild
type virus, while the C5 and C8 viruses exhibit a very
weakly demyelinating phenotype, similar to C12. This
suggests that the demyelination phenotype correlated
with the appearance of the Q159L mutation and before
the H716D and the replicase amino acid substitutions in
the evolution of the ‘‘C’’ culture.
DISCUSSION

An association between the Q159L substitution in S
and the loss of hepatotropism was demonstrated by the

We have previously shown that the group of fusion
delayed, nonhepatotropic MHV-A59 mutants isolated
from two independently infected glial cells had the same
two, and only two, amino acid substitutions relative to
wild type in the gene encoding the spike glycoprotein S.
The cleavage recognition site amino acid substitution
(H716D) clearly correlates with the delayed fusion phenotype, but not with loss of hepatotropism (Hingley et al.,
1994; Gombold et al., 1993). The other amino acid substitution, Q159L, appeared to correlate with the hepatotropism phenotype (Hingley et al., 1994, 1995; see Table 2).
We concluded this because the Q159L mutation first appeared in virus plaque purified from two independent
persistently infected glial cell cultures at 6 weeks postinfection, at the same time that the altered hepatotropism
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FIG. 2. Quantitation of demyelination induced by wild type MHV-A59 and the weakly demyelinating C12, B11 and B12 mutants. C57Bl/6 mice
were inoculated intracerebrally with various doses of wild type and mutant viruses. Animals surviving the acute infection were sacrificed at 30 days
postinfection, and spinal cords were analyzed for demyelination by staining with luxol fast blue all as described in the text. (A) Amount of
demyelination, expressed as the percentage of spinal cord quadrants containing demyelination, at each dose of virus inoculum. (B) Data used in
the graph in A. Demyelination values were rounded to the nearest whole number. (In this experiment all animals that were given the highest dose
of C12 and those at all doses of B12 survived acute infection).

phenotype became evident. The H716D mutation did not
appear until 12 weeks postinfection, along with the delayed fusion phenotype (Hingley et al., 1994; Table 2).
It was not possible to map unambiguously the hepatotropic phenotype to Q159L when the sequence of the
rest of the genome was not known. Furthermore, the
observation that C12, B11, and B12 have somewhat different pathogenic properties while possessing the same
sequence of S (Table 1; Hingley et al., 1994) suggested
that mutations outside of S must influence the pathogen-

esis of this virus. Since there is not yet available an
infectious cDNA clone for MHV, we were not able to
introduce individual mutations into the viral genome.
Therefore, we used an alternative method to map mutations that alter pathogenic properties; we sequenced the
entire 31-kb genome of C12.
Surprisingly, there were only five amino acid substitutions in the entire 31-kb genome of C12 after 16 weeks
of persistent culture in glial cells. This suggests that the
fidelity of the MHV polymerase is higher than commonly
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FIG. 3. Quantitation of demyelination induced by the ‘‘early’’ C3, C5, and C8 mutants. C57Bl/6 mice were inoculated intracerebrally with various
doses of mutant viruses. Animals surviving the acute infection were sacrificed at 30 days postinfection, and spinal cords were analyzed for
demyelination by staining with luxol fast blue all as described in the text. (A) Amount of demyelination, expressed as the percentage of spinal cord
quadrants containing demyelination, at each dose of virus inoculum. (B) Data used in the graph in A. Demyelination values were rounded to the
nearest whole number. (In this experiment all animals except three that were given the highest dose of C3 survived acute infection).

assumed (Lai, 1990; Adami et al., 1995) and/or that, during persistence in glial cell cultures, there is a strong
selective pressure against mutation within the genome.
Consistent with this observation was our finding that,
in the comparison of our MHV-A59 lab strain with the
published sequences, there were just 6 amino acid substitutions and 11 silent mutations. We do not think these
sequences differences between the wild type MHV-A59
parent of C12 and the published sequences are significant in terms of pathogenesis. The MHV-A59 used as
our wild type in these experiments (obtained from Dr. L.
Sturman) exhibits the same pathogenic properties as the
MHV-A59 (obtained from Dr. J. Leibowitz) that we used
for our previous pathogenesis studies (Lavi et al., 1984b)

and for sequencing of genes 1, 2a, 4, and 5 (Bonilla et
al., 1994; Budzilowicz and Weiss, 1987; Weiss et al., 1993;
Zoltick et al., 1990).
The only amino acid substitutions in the C12 genome
other than the two encoded in the S gene were three
amino acid substitutions in the replicase gene. There are
two amino acid substitutions encoded in ORF1a (P1699S
and M2196K) and one in ORF 1b, R1330S. The P1699S
substitution is in the predicted PLP-2 domain of ORF 1a
and the R1330S substitution is in the predicted helicase
domain of ORF 1b (Bredenbeek et al., 1990; Lee et al.,
1991) (see Fig. 1). It is difficult to predict whether the
mutation in PLP-2 is likely to be significant. The B11
mutant also has a mutation, albeit a different one from
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C12, V1798M in PLP-2. Numerous attempts in our lab
to detect an activity for PLP-2 had been unsuccessful,
suggesting that the PLP-2 domain does not encode an
active proteinase; if this were the case, then mutations
in this region of the replicase gene would not be expected to have a phenotype. However, recently, we have
found that a recombinant protein encoded in the predicted PLP-2 domain does indeed have a proteinase activity (H. Teng and S. R. Weiss, unpublished results).
Thus, if PLP-2 is a necessary activity for replication, these
mutations may be significant. The C12 mutation in ORF
1b is in the predicted helicase domain. The recent demonstration of an ATPase activity for a recombinant protein
encoded in the predicted helicase domain of ORF 1b
of the human coronavirus 229E (Heusipp et al., 1997)
supports the prediction that this is indeed a helicase
domain. It is likely that such a polypeptide might interact
with host cell proteins and thus influence tropism. The
third mutation is in ORF 1a, M2196KL, in a region of the
replicase that has not been assigned a function.
The AAUCUAAAC sequence observed preceding the
M gene of C12 (different from the wild type AAUCCAAAC)
is the sequence found in most of the intergenic regions
in the wild type genome (Budzilowicz et al., 1985; Bonilla
et al., 1994; Luytjes et al., 1987). Thus it is clear that this
sequence can function as an intergenic region. Since the
mechanism of generation of coronavirus mRNA is still
not clearly understood, the role of coronavirus conserved
intergenic regions is also not known. However, it is believed that intergenic regions play a role in the control
of subgenomic mRNA transcription, perhaps serving as
promoters for subgenomic mRNA synthesis (van der
Most and Spaan, 1995). Thus, it is possible that this
nucleotide change could effect transcription of the C12
mRNA encoding the M gene. We doubt that this is the
case as the levels of M protein in cells infected with C12
is approximately the same as in wild type infected cells
(unpublished data). While there is no evidence suggesting that any of the mutations in the C12 genome,
either silent or encoding amino acid substitutions, can
produce a change in replication or pathogenesis by effecting the secondary structure of the genome RNA, we
cannot completely rule out this possibility.
We show here that the appearance of the Q159L mutation within the ‘‘C’’ culture of persistently infected glial
cells, in addition to correlating with the loss of hepatotropism, also coincides with the development of the
weakly demyelinating phenotype. Further evidence that
the Q159L mutation is important in the demyelination
phenotype comes from our observations that the B11
and B12 mutants, isolated from another parallel glial cell
culture, are also weakly demyelinating (Fig. 2) and contain this mutation in the S gene (Hingley et al., 1994).
Thus it appears that the demyelination and hepatotropism phenotypes of C12 are both associated with Q159L,

rather than the replicase mutations. The relationship of
Q159L to virulence is, however, not as clear. The observation that the B12 mutant retains its virulence (Hingley
et al., 1994, Table 1) demonstrates that Q159L is not
sufficient for attenuation and furthermore that the loss of
hepatotropism does not necessarily lead to attenuation.
The hepatotropic, demyelinating C3 mutant also retains
its virulence while the nonhepatotropic, weakly demyelinating C5 and C8 mutants are somewhat attenuated although probably not as attenuated as C12 (data not
shown). Thus there may be other mutations in these viruses, absent in C12, that modify the virulence phenotype. The data discussed above and shown in Table 1
suggest there must be mutations outside of S that result
in the differences in hepatotropism between B11 and
C12, and differences in virulence between B12 and the
other mutants. It is possible that the three replicase mutations in C12 modify the pathogenic properties. We cannot
be sure of the effects of these mutations until we can
analyze recombinant viruses containing only the Q159L
mutation; such work is in progress.
The mechanism of MHV induced demyelination is to
this date still not well understood. There is mounting
evidence that both immune mediated components as
well as direct infection of virus are factors in the establishment of demyelination (Houtman and Fleming,
1996a). Our observation that for wild type MHV-A59 the
amount of demyelination was proportional to the log10 of
the virus inoculum (Fig. 2) argues that the amount of virus
in the CNS is important in the development of demyelination. This is consistent with the hypothesis that a direct
infection mechanism plays a significant role in demyelination (Houtman and Fleming, 1996a). Alternatively, the
larger virus inoculum could result in a larger number of
persistently infected cells in the CNS to be damaged by
the immune response.
MHV acute infection includes encephalitis and virus
replication at high titer in the CNS. It has been shown
that while infectious virus cannot be recovered from the
CNS after the acute infection, viral RNA persists in the
white matter of the CNS probably throughout the lifetime
of the mouse (Lavi et al., 1984a; Adami et al., 1995). The
group of mutants that we are working with all cause
acute encephalitis, but at least in the case of the three
that we have examined carefully (C12, B11, B12), there
are only minimal levels of demyelination and only at very
high levels of virus inoculated. Thus encephalitis does
not necessarily lead to demyelination. Several other labs
have reported mutants of the JHM strain of MHV, in which
encephalitis and demyelination are dissociated. For example the attenuated JHM2.2-V-1 mutant (Fleming et al.,
1986, 1987) and the MHV-4 mutant 5A13.5 mutant (Dalziel
et al., 1986; Fazakerley et al., 1992) cause little encephalitis but do induce significant demyelinating disease. Both
of these mutants were selected by resistance to mono-
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clonal antibodies directed against epitopes in the S gene;
thus, the change in pathogenic phenotype is likely to
map to S. The mutants we have selected from persistently infected glial cells (C12, B11, and B12 for example)
are, to our knowledge, the first examples of MHV mutants
in which encephalitis occurs without subsequent demyelinating disease.
The location of the Q159L amino acid substitution
within the predicted receptor binding domain (Kubo et
al., 1994) of S suggests that this mutation may play a
role in the development of demyelination and hepatitis
by affecting the interaction of S and the viral receptor.
The inability of C12 to interact with the receptor on one
or more liver cell types would be a reasonable explanation for the lack of hepatitis following infection with C12.
The difference in the ability of C12 and wild type virus
to induce demyelination could also be related to the tropism for a certain cell type. While we have shown that
C12 replicates at least to wild type levels in the CNS
during acute infection and is found in neurons with a
similar localization in the limbic system (Hingley et al.,
1994), we are currently studying the spread of the two
viruses to various cell types and the persistence in the
CNS after the acute disease and viral clearance occurs.
The region defined as a receptor binding domain includes the amino terminal 330 amino acids of S1 (Kubo
et al., 1994). Amino acid Q159, and the region surrounding it, is conserved in 9/10 MHV strains (Suzuki and
Taguchi, 1996); interestingly the MHV-S strain, a strain
exhibiting low pathogenicity, has the same Q159L substitution observed in our mutants. There is, however, no
direct evidence that Q159L is involved in receptor interaction; the Q159L amino acid substitution could effect
hepatotropism and demyelination via another mechanism, perhaps due to a step in replication after binding
and entry.
Another possible explanation for the different pathogenic phenotypes of C12, B11, and B12, as compared
with wild type MHV-A59, is that an amino acid substitution in the S protein could result in an altered immune
response and this would then result in a change in the
ability to induce hepatitis and demyelination. This is a
possibility as there is clearly an immune mediated component in MHV induced demyelination (Fleming et al.,
1993; Kyuwa et al., 1991; Houtman and Fleming, 1996b).
However, we think that this is unlikely because it is difficult to imagine how the Q159L mutation might effect the
immune response to MHV as there is no evidence for
an epitope recognized by either a CD4/ T cell or a CD8/
T cell in the receptor binding region (the region around
the Q159L mutation) of S of the JHM virus (Stanley Perlman, pers. commun.). Thus we think that it is unlikely
that the altered demyelination phenotype of C12, B11,
and B12 is due to an altered immune response but rather
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to a change in viral tropism, perhaps through receptor
utilization.
We are currently using targeted recombination technology developed by Dr. Paul Masters (Masters et al.,
1994; Fischer et al., 1997) to introduce Q159L alone into
the genome of wild type MHV-A59. This will allow us to
determine unambiguously the effects of this amino acid
substitution alone on pathogenesis and interaction of the
mutant protein with the MHV receptor.
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